

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Teveten 600 mg, film-coated tablets

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains eprosartan mesylate equivalent to 600 mg eprosartan.

Excipient with known effect:

Each film-coated tablet contains lactose.

*For the full list of excipients, see section 6.1.*

## 3 PHARMACEUTICAL FORM

Film-coated tablet

*Product imported from Czech Republic:*

Capsule-shaped, white, film-coated tablet marked "5046" on one side and no inscription on the other side.

## 4 CLINICAL PARTICULARS

As per PA2010/017/002

## 5 PHARMACOLOGICAL PROPERTIES

As per PA2010/017/002

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Tablet Core:

Lactose

Microcrystalline cellulose

Pregelatinised starch

Crospovidone

Magnesium stearate

Tablet Coating:

Hypromellose (E464)

Titanium dioxide (E171)

Macrogol 400

Polysorbate 80 (E433)

### 6.2 Incompatibilities

Not applicable.

### 6.3 Shelf life

The shelf-life expiry date of this product is the date shown on the container and outer carton of the product on the market in the country of origin.

#### **6.4 Special precautions for storage**

Do not store above 25°C.Keep the blister in the outer carton.

#### **6.5 Nature and contents of container**

Over-labelled cardboard carton containing 2 blister strips (14 tablets per strip).  
Pack size of 28 tablets.

#### **6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product**

No special requirements.

### **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

IMED Healthcare Ltd.  
Unit 625 Kilshane Avenue  
Northwest Business Park  
Ballycoolin  
Dublin 15  
Ireland

### **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA1463/091/001

### **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 31<sup>st</sup> January 2014

### **10 DATE OF REVISION OF THE TEXT**

March 2022